Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95Returned $1.0 billion to shareholders through share repurchases and dividends during FY2026, an increase of more than 70%Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com